Key result
New diagnostic algorithms (H2FPEF, HFA-PEFF) and biomarkers allow for the early detection of HFpEF by accounting for patient heterogeneity and pathogenesis.
Why the study?
The 2016 diagnostic algorithm does not account for the heterogeneity of patients and the course of HFpEF, prompting the evaluation of newer diagnostic algorithms and biomarkers.
Do new diagnostic algorithms (H2FPEF, HFA-PEFF) and biomarkers improve the early detection of HFpEF in patients with hypertension and obesity?
Do new diagnostic algorithms (H2FPEF, HFA-PEFF) and biomarkers improve the early detection of HFpEF in patients with hypertension and obesity?
New diagnostic algorithms such as H2FPEF and HFA-PEFF may improve the early detection of HFpEF in complex patients with comorbidities like hypertension and obesity.
Heart failure with preserved ejection fraction (HFpEF) is a complex clinical syndrome associated with frequent hospitalizations, high mortality rates, and an absence of proven effective therapy. This type of heart failure is often accompanied by comorbidity that complicate the diagnosis of the underlying disease. The algorithm developed in 2016 does not take into account the heterogeneity of patients and course of HFpEF. Recently, new diagnostic algorithms (H2FPEF, HFA-PEFF) and biomarkers have appeared that allow detecting HFpEF at an early stage, taking into account the pathogenesis, which may contribute to development of new effective treatment methods.
No takes yet. Share an insight, caveat, or question.
Vasyuk et al. (2021) conducted a review in Heart failure with preserved ejection fraction (HFpEF) with hypertension and obesity. Diagnostic algorithms (H2FPEF, HFA-PEFF) and biomarkers was evaluated. New diagnostic algorithms (H2FPEF, HFA-PEFF) and biomarkers allow for the early detection of HFpEF by accounting for patient heterogeneity and pathogenesis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: